Alterity presents new ATH434 Phase 2 analyses in multiple system atrophy at MDS Congress 2026
Alterity Therapeutics has presented additional analyses from its randomised, double-blind, placebo-controlled ATH434-201 Phase 2 trial in multiple system atrophy (MSA) at the 2026 International Congress of Parkinson’s Disease… read more.




